Intranasal Vaccine
- January 29, 2022
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
Intranasal Vaccine
Subject – Science and Tech
Context – Intranasal booster trials get DCGI nod
Concept –
- An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
- The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa.
Advantages
- Non-invasive, Needle-free.
- Ease of administration – does not require trained health care workers.
- Elimination of needle-associated risks (injuries and infections).
- High compliance (Ideally suits for children’s and adults).
- Scalable manufacturing – able to meet global demand.
- Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.